- 24/7 Wall St.•17 hours ago
While worries about interest rates increases remain, it looks as though growth stocks still are the best avenue heading into the final two months of the year.
- Investor's Business Daily•yesterday
Alkermes and Lundbeck are cannibalizing Johnson & Johnson's anti-psychosis sales, Credit Suisse said Monday.
- Insider Monkey•2 days ago
At the end of last week, we highlighted Alkermes Plc (NASDAQ:ALKS) as being one of the biggest movers in the biotechnology space for the month. The company had just put out topline data from its lead major depressive disorder (MDD) pivotal trial, and the data hit on its primary and a number key secondaries. Not […]
Alkermes plc (ALKS)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Day's Range||53.65 - 56.71|
|52wk Range||27.14 - 80.71|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-29.81|
|Avg Vol (3m)||1,064,449|
|Dividend & Yield||N/A (N/A)|